Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.

ABSTRACT:

Introduction

Though 85% of children and young adults with acute lymphoblastic leukemia (ALL) are cured, until recently, the prognosis of relapsed or refractory disease has been dismal. The advent of chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed/refractory ALL. The most well-studied, successful CARs are autologous, murine-based anti-CD19 CARs, but new constructs are currently under clinical investigation.

Areas covered

This review describes the history and design of CAR T cells, clinical trial outcomes of anti-CD19 and newer CARs, treatment-related toxicities including cytokine release syndrome and neurotoxicity, and issues with resistance and relapse. A search of PubMed and clinicaltrials.gov spanning from 2012-present was used to s

SUBMITTER: Myers RM 

PROVIDER: S-EPMC7905709 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature